Home > Products > CD64 & EGFR
> Recombinant Anti-CD64 x Anti-EGFR Bispecific Antibody (Tandem scFv)
Recombinant Anti-CD64 x Anti-EGFR Bispecific Antibody (Tandem scFv) (CAT#: BSFV-125)
Recombinant Anti-CD64 x Anti-EGFR Bispecific Antibody (Tandem scFv) is designed to be expressed as a scFv from an anti-CD64 antibody variable domains fused with a scFv from an anti-EGFR antibody variable domains. It contains a His-tag at the C/N terminus for affinity purification. The BsAb exits as monomer in reducing and non-reducing conditions. This BsAb can retarget neutrophils cells to tumor cells. It is designed for the research of Head and neck cancer; Colorectal cancer (CRC); Glioblastoma multiforme (GBM); Squamous cancer; Glioblastoma; Medulloblastoma; Non-small cell lung cancer (NSCLC); Renal cell cancer (RCC); Solid tumors therapy.
Head and neck cancer; Colorectal cancer (CRC); Glioblastoma multiforme (GBM); Squamous cancer; Glioblastoma; Medulloblastoma; Non-small cell lung cancer (NSCLC); Renal cell cancer (RCC); Solid tumors
FCGR1A; Fc fragment of IgG receptor Ia; CD64; FCRI; CD64A; IGFR1; Cluster of Differentiation 64; FcγRI; FCGR1B; FCGR1C; immunoglobulin G Fc receptor high affinity I; Fc gamma RI
There are currently no customer reviews or questions for Recombinant Anti-CD64 x Anti-EGFR Bispecific Antibody (Tandem scFv) (BSFV-125). Click the button below to contact us or submit your feedback about this product.